October 5, 2011New England Journal of Medicine2,790 citationsOpen Access
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
The addition of 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival among women with HER2-positive breast cancer. The risk-benefit ratio favored the nonanthracycline TCH regimen over AC-T plus trastuzumab, given its similar efficacy, fewer acute toxic effects, and lower risks of cardiotoxicity and leukemia. (Funded by Sanofi-Aventis and Genentech; BCIRG-006 ClinicalTrials.gov number, NCT00021255.).